Barclays analyst Andrew Mok lowered the firm’s price target on Centene (CNC) to $91 from $97 and keeps an Overweight rating on the shares post the Q3 report. While rates appear to be trending in the right direction, 1/1 rates remain the big swing factor in Medicaid margin progression and the company’s 2025 earnings growth, the analyst tells investors in a research note.
Don't Miss out on Research Tools:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNC: